Business Context and Reporting Period
This Form 8-K Current Report was filed by Outlook Therapeutics, Inc. on June 23, 2020, covering events occurring on June 19, 2020. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Monmouth Junction, New Jersey. Its common stock and Series A warrants trade on The Nasdaq Stock Market LLC under the symbols OTLK and OTLKW, respectively.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance changes.
Material Changes
- Board Expansion: The Board of Directors increased its size from seven to eight members.
- New Appointment: Andong Huang was appointed as a Class II director effective June 19, 2020. His term extends until the 2021 annual meeting of stockholders or until his successor is elected.
- Designation: Mr. Huang was designated by Syntone Ventures LLC pursuant to a Stock Purchase Agreement dated May 22, 2020. He serves as Vice President, Business Development of Syntone Technologies Co. Ltd., an affiliate of Syntone Ventures LLC.
Compensation and Governance Details
- Director Compensation: Mr. Huang will be compensated in accordance with the Company's non-employee director compensation policy effective October 1, 2019.
- Equity Grant: Under the automatic grant program, Mr. Huang received an option to purchase 25,000 shares of common stock under the 2015 Equity Incentive Plan.
- Option Terms: The exercise price is $1.35 per share (the closing sales price on June 19, 2020). The options vest annually over three years, subject to continuous service, with acceleration provisions in the event of a change of control. The term is 10 years.
- Indemnification: The Company entered into a standard indemnification agreement with Mr. Huang, filed as Exhibit 10.12 to the Company's Form S-1 registration statement.
Investor Verification Checklist
- Verify the terms of the Stock Purchase Agreement with Syntone Ventures LLC filed on May 28, 2020, to understand the context of Mr. Huang's designation.
- Review the Company's 2015 Equity Incentive Plan for specific details regarding vesting schedules and change of control definitions.
- Confirm the current status of the Board composition and any subsequent changes since the June 19, 2020 appointment.
- Check the Company's proxy statement filed on February 14, 2020, for the full text of the non-employee director compensation policy.